Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. Curcumin is a compound found in plants that may prevent colon cancer from forming. This phase II trial is studying how well curcumin works in preventing colon cancer in smokers with aberrant crypt foci.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Curcumin for the Chemoprevention of Colorectal Cancer

NCT00118989

Adenomatous Polyps

TERMINATED NA

The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon

NCT00176618

Aberrant Crypt Foci

TERMINATED NA

Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue

NCT01294072

Colon Cancer

RECRUITING NA

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

NCT06063486

Clonal Cytopenia of Undetermined Significance Essential Thrombocythemia Myelodysplastic Syndrome +2 more

RECRUITING PHASE2

Curcumin Biomarker Trial in Head and Neck Cancer

NCT01160302

Head and Neck Cancer

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine mean percentage change from baseline in prostaglandin E2 (PGE2) within ACF pre and post 30 days of curcumin administration at a specified dose.

SECONDARY OBJECTIVS:

I. To determine mean percentage change from baseline in 5-hydroxy-eicosatetraenoic acid (5-HETE) within ACF pre and post 30 days of curcumin administration at a specified dose.

II. To determine mean percentage change from baseline in PGE2 and 5-HETE within comparison normal mucosa pre and post 30 days of curcumin administration at a specified dose.

III. To quantify corresponding enzyme changes in the cyclooxygenases (COX-1, COX-2,) and lipoxygenase (5-LOX) protein abundance. Semi-quantitative changes in these proteins will be measured by western blotting and correlated with changes in prostaglandins and leukotrienes respectively.

IV. Document changes in total ACF number. V. Determine proliferation by Ki-67 IHC in rectal mucosa pre and post therapy and correlate with changes in ACF number and size.

VI. Determine curcumin concentration in rectal mucosa after 30 days therapy and correlate with PGE2 and 5-HETE changes described above.

VII. Measure glutathione peroxidase (GPx) activity within the colon pre and post therapy as an indirect marker of reduced oxidative stress within the colonic epithelium.

VIII. Ensure safety of all participants during course of study investigation. IX. Determine the curcumin concentration in plasma before and after treatment.

OUTLINE: This is a multicenter, nonrandomized, uncontrolled study.

Patients receive 1 of 2 doses of oral curcumin once daily. Treatment continues for 30 days in the absence of unacceptable toxicity or disease progression.

Blood and tissue biopsies are obtained by sigmoidoscopy or colonoscopy at baseline and at day 30 for correlative biomarker studies. The change in prostaglandin E\_2 (PGE\_2) is assessed by enzyme immunoassay, 5-hydroxy-eicosatetraenoic acid (5-HETE) by high-performance liquid chromatography, cyclooxygenases (COX-1 and COX-2) and 5-lipoxygenase (5-LOX) by western blotting, Ki-67 by immunohistochemistry, and glutathione peroxidase (GPx) by spectrophotometric assay.

After completion of study therapy, patients are followed at 1 week.

PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy, no Evidence of Disease Tobacco Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2g (curcumin)

Patients receive 2 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.

Group Type EXPERIMENTAL

laboratory biomarker analysis

Intervention Type OTHER

Correlative studies

pharmacological study

Intervention Type OTHER

Correlative studies

curcumin

Intervention Type DRUG

Given orally

4g (curcumin)

Patients receive 4 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.

Group Type EXPERIMENTAL

laboratory biomarker analysis

Intervention Type OTHER

Correlative studies

pharmacological study

Intervention Type OTHER

Correlative studies

curcumin

Intervention Type DRUG

Given orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

laboratory biomarker analysis

Correlative studies

Intervention Type OTHER

pharmacological study

Correlative studies

Intervention Type OTHER

curcumin

Given orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

pharmacological studies C.I. 75300 C.I. Natural Yellow 3 CU Diferuloylmethane

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Current smoker with \> 3 pack-year total smoking history
* Subjects taking NSAIDS or ASA \< 10 days month are eligible but must undergo 14 day washout and refrain from use during the study
* Subjects who are:

* Having a clinically indicated screening/surveillance colonoscopy (e.g. due to risk factors, personal history, or symptoms) OR
* Not having a colonoscopy but are otherwise eligible. These subjects would undergo a flexible sigmoidoscopy.
* ECOG performance status 0-2 (Karnofsky \> 60%)
* No severe organ dysfunction which might increase bleeding risk:

* Demonstrated by: Normal hematologic status (WBC \> 3,000/mm\^3, hemoglobin \> 10.0 gm/dl, and platelet-count \>100,000/mm\^3), normal hepatic function (bilirubin \< 1.5 mg/dl, transaminases \< 1.5x institutional norms), and normal renal function (serum creatinine \< 2.0 mg/dl, documented in clinical chart 28 days prior to enrollment
* Healthy current smokers (1 cigarette in previous yr) with \> 3-pack year of cigarette smoking and able to provide written informed consent; there are no gender restrictions
* The effects of curcumin on the developing human fetus at the recommended therapeutic dose are unknown; for this reason women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

* NSAID or ASA use \> 10 days /month; any current glucocorticoid use or omega 3-fatty acid supplement use
* Evidence of the following chronic medical conditions such as:

* Pregnant or lactating women and/or women who are contemplating pregnancy during the duration of the protocol
* History of chronic inflammatory bowel disease or prior pelvic irradiation
* History of peptic ulcer disease (PUD) endoscopically confirmed \< 5 yrs from enrollment date
* Newly diagnosed colorectal cancer or advanced adenoma \< 1 yr from enrollment
* Unspecified history of bleeding or coagulation disorder reported by patient or in medical history
* Hereditary Colon Cancer syndromes (FAP or HNPCC)
* Participants may not be receiving any other investigational agents
* History of contact dermatitis from turmeric
* Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant women are excluded from this study because curcumin is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with curcumin, breastfeeding should be discontinued if the mother is treated with curcumin

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Frank Meyskens

Role: PRINCIPAL_INVESTIGATOR

Chao Family Comprehensive Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chao Family Comprehensive Cancer Center

Orange, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States